A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 7, 2016

Primary Completion Date

January 3, 2022

Study Completion Date

January 3, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

Daratumumab

DRUG

Durvalumab

DRUG

Pomalidomide

DRUG

Dexamethasone

Trial Locations (64)

2100

Local Institution - 552, Copenhagen

Rigshospitalet University Hospital, Copenhagen

5530

Cliniques Universitaires UCL de Mont-Godine, Yvoir

7100

Local Institution - 551, Vejle

Vejle Hospital, Vejle

8000

AZ St-Jan Brugge Oostende AV, Bruges

19104

Perelman Center for Advanced Medicine, Philadelphia

University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia

20817

Center For Cancer and Blood Disorders, Bethesda

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

Local Institution - 452, Madrid

28041

Hospital 12 de Octubre, Madrid

28100

A.O.U. Maggiore della Carità, Novara

Local Institution - 353, Novara

30322

Emory University Hospital, Atlanta

33394

Hospital de Cabuenes, Gijón

Local Institution - 451, Gijón

35128

Azienda Ospedaliera di Padova, Padua

Local Institution - 355, Padua

37203

Sarah Cannon Research Institute, Nashville

Tennessee Oncology Nashville Drug Development Unit, Nashville

40138

Local Institution - 354, Bologna

Policlinico S. Orsola - Malpighi, Bologna

56126

A.O. Universitaria Ospedale S.Chiara Dip.Oncologia, Div. Ematologia, Pisa

60637

University of Chicago Medical Center, Chicago

63110

Washington University, St Louis

69115

Local Institution - 203, Heidelberg

Universitatsklinikum Heidelberg, Heidelberg

72076

University Hospital Tubingen, Tübingen

80218

Colorado Blood Cancer Institute, Denver

Local Institution - 007, Denver

90146

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo

91010

City of Hope National Medical Center, Duarte

97080

Local Institution - 201, Würzburg

Universitatsklinikum Wuerzburg, Würzburg

98104

Swedish Medical Center, Seattle

90095-1752

UCLA Division of Hematology Oncology, Los Angeles

02115

Dana-Farber Partners Cancer Care, Inc., Boston

07601

Hackensack University Medical Center, Hackensack

B-3000

Universitaire Ziekenhuizen Leuven Univeristy Hospitals Leuven, Leuven

E2L 3L6

Local Institution - 103, Saint John

Saint John Regional Hospital, Saint John

M5G 2M9

Local Institution - 104, Toronto

Princess Margaret Cancer Centre, Toronto

H1T 2M4

Hopital Maisonneuve-Rosemont, Montreal

Local Institution - 101, Montreal

H4A 3J1

MUHC Glen Site, Montreal

DK-5000

Local Institution - 553, Odense

Odense University Hospital, Odense

01307

Universitatsklinikum Carl Gustav Carus an der TU Dresden, Dresden

08907

Hospital Durán i Reynals - Instituto Catalàn de Oncologìa ICO, Barcelona

Local Institution - 453, Barcelona

60 Gothenburg

Sahlgrenska University Hospital, Gothenburg

221 85

Local Institution - 501, Lund

Skanes Universitetssjukhus Malmo, Lund

SE-141 86

Local Institution - 502, Stockholm

SE-14186

Karolinska Universitetssjukhuset - Huddinge, Stockholm

EC1A 7BE

St. Bartholomew's and The Royal London Hospital, London

M20 4BX

Christie Hospital, Manchester

0X3 7LE

Local Institution - 252, Oxford

Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford

SM2 5PT

Local Institution - 253, Sutton (Surrey)

Royal Marsden Hospital, Sutton (Surrey)

WV10 0QP

The Royal Wolverhampton Hospital NHS Trust, Wolverhampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY